Actively Recruiting
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
Led by General Hospital of Shenyang Military Region · Updated on 2025-08-26
174
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.
CONDITIONS
Official Title
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- A definite diagnosis of liver cirrhosis and overt hepatic encephalopathy
- Serum albumin level between 23 and 30 g/L
- Age 18 years or older
- Signed informed consent
You will not qualify if you...
- Contraindications to human albumin infusion
- History of transjugular intrahepatic portosystemic shunt
- Diagnosis of acute liver failure
- Severe heart and/or lung diseases
- Psychiatric or nervous system diseases
- Pregnant or lactating
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
Shenyang, Liaoning, China
Actively Recruiting
Research Team
X
Xingshun Qi
CONTACT
Q
Qianqian Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here